Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2011;12(7):1671-4.

Efficacy of Orally Administered Lentinula Edodes Mycelia Extract for Advanced Gastrointestinal Cancer Patients Undergoing Cancer Chemotherapy: A Pilot Study

Affiliations
  • PMID: 22126542
Free article

Efficacy of Orally Administered Lentinula Edodes Mycelia Extract for Advanced Gastrointestinal Cancer Patients Undergoing Cancer Chemotherapy: A Pilot Study

Kiyotaka Okuno et al. Asian Pac J Cancer Prev. .
Free article

Abstract

This study investigated the influence of Lentinula edodes mycelia extract (LEM), an oral immunomodulator, on immune function and adverse events from chemotherapy. Subjects comprised 1 gastric and 7 colorectal cancer patients. The first course of treatment was chemotherapy alone and the second was chemotherapy plus concomitant administration of LEM. Adverse events and interferon (IFN)-γ production by CD4+ T, CD8+ T and CD56+ NK/NKT cells were evaluated at the end of each course. Grade 1 or 2 adverse events were observed at the end of the first course for 6 of 8 patients. In comparison, no patients displayed any adverse events at the end of the second course. Tendencies toward improved IFN-γ production by CD4+ T, CD8+ T and CD56+ NK/NKT cells was also seen. These results suggest that concomitant use of LEM with chemotherapy can decrease the incidence of adverse effects from cancer chemotherapy among patients with advanced cancer.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback